Biomérieux: Invest Securities still a buyer, but cuts TP
(CercleFinance.com) - Invest Securities maintains its buy rating on Biomérieux shares, while reducting its target price for them from E122 to E118 (cp: E95, +0.
7%), after the company reported unsurprising 2022 results.
The strong growth in non-PR panels, the continued expansion of the installed base and the rebound in immunoassays are all positive signals in the short term, the broker said, adding that the group has reiterated its 2023 targets.
The analyst says that the market is hiding many levers that have not yet delivered, which will enable the group to digest the post-Covid era effectively. Biomérieux also has sufficient funds to make new acquisitions to reinforce its medium-term prospects.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
7%), after the company reported unsurprising 2022 results.
The strong growth in non-PR panels, the continued expansion of the installed base and the rebound in immunoassays are all positive signals in the short term, the broker said, adding that the group has reiterated its 2023 targets.
The analyst says that the market is hiding many levers that have not yet delivered, which will enable the group to digest the post-Covid era effectively. Biomérieux also has sufficient funds to make new acquisitions to reinforce its medium-term prospects.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.